Navigation Links
Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
Date:9/9/2008

BETHLEHEM, Pa., Sept. 9 /PRNewswire/ -- A seven and a half-year study conducted in the In Vitro Fertilization Cleanroom Laboratory of the Lehigh Valley Hospital and Health Network found that the use of ultraviolet C or "UVC" lights installed in the HVAC system had a clinically significant impact on clinical pregnancy rates (CPR). In presenting the findings at the annual meeting of the American Society for Reproductive Medicine (ASRM), Kathryn C. Worrilow, Ph.D. reported that the + beta and CPR increased by an average of 17.8% and 18.2%, respectively, following 10 of the 13 change-outs of the Steril-Aire UVC Emitters(TM) over the test period.

Clinical success in an IVF lab is critically dependent upon the quality of the ambient air, which in turn, is directly dependent upon the HVAC system. The study led by Dr. Worrilow tracked three key components in the HVAC system -- particulate filters, gas phase filters and UVC lights -- and the timing of their replacement -- to determine whether these individual components affected markers of preimplantation embryogenesis and clinical pregnancy rates.

According to the findings, "There were no statistically significant differences...associated with the replacement of the particulate or gas phase filters in Testing Quarters 1-48. In contrast, immediately following 10 of the 13 UVC Emitter change-outs, the + beta hCG and clinical pregnancy rates increased 17.8% and 18.2%, respectively."

The study goes on to say: "UVC energy will destroy 90 -- 99% of airborne microbial contaminants. By targeting the DNA and RNA of microorganisms, UVC degrades and abates the proliferation of airborne and surface embryotoxic organics. Of equal significance to the developing embryo is the suggested impact of UVC irradiation on the degradation of VOCs. Our work has demonstrated that VOC levels as low as 2.2 ppb can be embryotoxic to the embryo cultured in vitro."

The authors conclude: "Although the use of UVC light represents a departure from the standard HVAC design used in many IVF laboratories, the current study suggests that the use of UVC germicidal technology in the HVAC system serving the IVF laboratory may play a critical role in providing optimal ambient air towards improved clinical outcomes. The current study demonstrated that a clinically significant relationship existed between the replacement of the UVC Emitters and the associated clinical pregnancy rates."

Robert Scheir, Ph.D., president of Steril-Aire, Inc., states: "This new data provides scientific evidence of the germicidal benefits of UVC technology. The potential benefits are far-reaching: not only for the potential to improve CPR in IVF clinics, but also for enhancing infection control in hospitals and healthcare environments, and for maintaining better ambient air in medical and pharmaceutical manufacturing clean rooms."

Scheir adds: "The study also confirms the importance of adequate UVC output and changeout frequency in achieving desired results. The study used high-output Steril-Aire UVC lamps with a changeout schedule of 6-9 months. In the 3 of 13 UVC replacement test quarters that did not result in improved clinical pregnancy rates, outside factors may have played a role in the outcomes. As long as the lamps were functioning properly and were changed on schedule, results were consistently positive. The message to anyone using UVC is that it is critical to select a device with adequate output and to replace the device consistently at required intervals to maintain that output. Otherwise, germicidal effectiveness will be diminished."

For further information, visit http://www.steril-aire.com.


'/>"/>
SOURCE Steril-Aire, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe
2. Neuralstem Reports Second Quarter Financial Results and Highlights
3. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
4. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
5. Isis Reports Financial Results and Highlights for Second Quarter of 2008
6. Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
7. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
8. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
11. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
Breaking Biology Technology:
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
Breaking Biology News(10 mins):